I'm LongbridgeAI, I can summarize articles.Stryker Corp reported Q2 2026 revenue of $6.59B and diluted EPS of $3.3, up 9.4% and 44.1% year-over-year respectively. Growth was driven by higher unit volumes in MedSurg, Neurotechnology, and Orthopaedics. Net income rose to $1.28B. Gross margin improved due to tariff reversals and reduced inventory amortization, while cost discipline supported operating margin gains.
Stryker Corp reported second-quarter 2026 results with revenue of $6.59B and diluted EPS of $3.3, driven by higher unit volumes across MedSurg, Neurotechnology and Orthopaedics and resulting in stronger net earnings versus the year-ago quarter.
Financial Highlights
| Metric | Current quarter | Prior year quarter | YoY change |
| Revenue¹ | $6.59B | $6.02B | 9.4% |
| Net income² | $1.28B | $884M | 44.3% |
| Diluted EPS³ | $3.3 | $2.29 | 44.1% |
¹ Reported as “Net sales”. ² Reported as “Net earnings”. ³ Reported as “Diluted earnings per share of common stock”.
Business Highlights
- Revenue growth was broad-based with MedSurg and Neurotechnology leading the expansion; Orthopaedics and Trauma/Extremities also posted notable unit-volume gains.
- U.S. sales rose while international revenue grew faster, with foreign exchange contributing roughly 0.4–1.1% to growth.
- Gross margin improved due to tariff reversals and reduced inventory step-up amortization; the company continues to manage impacts from a prior cybersecurity incident that affected production in Q1.
- Continued cost discipline, structural optimization and integration efforts supported operating margin and adjusted EPS improvements.
Original SEC Filing: STRYKER CORP [ SYK ] - 10-Q - Jul. 31, 2026